Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification

Muto, Reiji; Miyoshi, Hiroaki; Sato, Kensaku; Furuta, Takeshi; Muta, Hiroko; Kawamoto, Keisuke; Yanagida, Eriko; Yamada, Kyohei; Ohshima, Koichi

doi:10.1002/cam4.1805

Cited by 49 publications

(39 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignant lymphoma was predominantly perceived in males compared to females. Studies from Saudi Arabia and other countries have shown similar findings [16] [17]. In this study, approximately 83.3% of the cases of HL were males, which is very high percentage compared to other reports [16].…”

Section: Discussionsupporting

confidence: 82%

Epidemiology and Patterns of Malignant Lymphoma in Northern Saudi Arabia

Elasbali¹,

Alharbi²,

Alonzi³

et al. 2018

OJBD

View full text Add to dashboard Cite

Objective: The objective of this study was to appraise the epidemiology and patterns of malignant lymphoma in Northern Saudi Arabia. Methodology: A full reportage of data regarding malignant lymphoma was retrieved from the King Khalid Hospital, Hail, Northern Saudi Arabia, comprising records of malignant lymphoma from 2009 to 2016. Results: A review of 120 blood cancers records revealed 47/120 (39.2%) cases of lymphomas, 39 (83%) were Non-Hodgkin lymphoma (NHL), 6 (12.8%) were HL and 2 (4.2%) B-cell lymphomas. The overall crude incidence rate CIR) of lymphomas (from 2009 to 2016) was 6.7 per 100,000 persons of the Hail region population. The mean CIR per year was 0.84 per 100,000 persons. Conclusion: The prevalence of malignant lymphoma is relatively higher in northern Saudi Arabia with predominance of NHL amongst elder population.

show abstract

Section: Discussionsupporting

confidence: 82%

Epidemiology and Patterns of Malignant Lymphoma in Northern Saudi Arabia

Elasbali¹,

Alharbi²,

Alonzi³

et al. 2018

OJBD

View full text Add to dashboard Cite

show abstract

“…The ratios of R-G, R/R-G, P-G, and Ch-G in MTX-EBV+DLBCL and MTX-DLBCL-NOS were 62%, 3%, 17%, 17%, and 26%, 6%, 36%, 26%, respectively. The rate of regressive LPD (R-G+R/R-G) was higher in MTX-EBV+DLBCL than in MTX-DLBCL-NOS (65% and 32%, respectively), supporting the previous report 58 . The ratio of patients with RRE in MTX-EBV+DLBCL and MTX-DLBCL-NOS was low (4% and 6%, respectively).…”

Section: Clinical Management Of Mtx-lpdsupporting

confidence: 86%

“…Although MTX-EBV+DLBCL is female dominant (71%), MTX-DLBCL-NOS has a lower incidence rate in females (59%). Mean ages at the development of MTX-DLBCL are similar between MTX-EBV+DLBCL and MTX-DLBCL-NOS (66 and 68 years, respectively, Table 1), which is similar to de novo DLBCL 58 . In both types of MTX-DLBCL, the most common AID was RA, and the duration of AID and MTX administration was over 10 and 5 years, respectively.…”

Section: Clinical Management Of Mtx-lpdmentioning

confidence: 58%

“…Regarding the laboratory data for MTX-DLBCL in our previous study, 16 the median serum levels of LDH, CRP, and sIL-2R in EBV+DLBCL and DLBCL-NOS were 240 IU/L, 1.4 mg/dL, 1440 U/mL, and 208 IU/L, 4.7 mg/dL, and 1525 U/mL, respectively, demonstrating similar trends between the two types of MTX-DLBCL. The EBV latency in MTX-EBV+DLBCL was type II dominant 58 …”

Section: Clinical Management Of Mtx-lpdmentioning

confidence: 95%

See 1 more Smart Citation

Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders

Tokuhira¹,

Tamaru²,

Kizaki³

2019

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPD), a category of immunodeficiency-associated LPD according to the World Health Organization classification, is associated with immunosuppressive drugs (ISDs). Several factors, including autoimmune disease (AID) activity, Epstein-Barr virus (EBV) infection, ISD usage, and aging, influence the development of OIIA-LPD, resulting in complicated clinical courses and outcomes. Most OIIA-LPD develops in patients with rheumatoid arthritis using methotrexate (MTX-LPD). The management of MTX-LPD is based on the clinical course, i.e., with/without regression, with/without relapse/regrowth event (RRE), LPD subtype, and ISDs for AIDs after LPD development. There are three clinical courses after ISD withdrawal: regressive LPD without relapse/regrowth (R-G), regressive LPD with RRE (R/R-G), and persistent LPD (P-G). The majority of EBV+ diffuse large B-cell lymphomas are classified in R-G, whereas classic Hodgkin lymphoma is generally classified in R/R-G. Polymorphic LPD (P-LPD) in MTX-LPD develops with heterogeneous pathological features similar to monomorphic LPD. Chemotherapy for MTX-LPD is selected according to that for de novo LPD, although the strategy for aggressive P-LPD and non-specific LPD is not well established. The absolute lymphocyte count in the peripheral blood has been suggested as a candidate marker for MTX-LPD development and RRE. Several clinical issues, including correct diagnosis among overlapping clinicopathological features in MTX-LPD and clinical management of LPD by ISDs other than MTX, require further investigation.

show abstract

“…In this study, we found that the prevalence of FL was also increased in Korea. A recent report also showed an increasing prevalence of FL in Japan, with 6% between 1996 and 2000, 18.3% between 2000 and 2006, and 22.4% between 2007 and 2014 [15]. The age of onset for FL was also found to be lower (52-54 years) in Asian countries than that in international studies (59 years) [16].…”

Section: Discussionmentioning

confidence: 94%

Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study

Jung

Huh

et al. 2019

J Hematopathol

View full text Add to dashboard Cite

To determine the relative frequency and change of malignant lymphoma in Korea according to the 4th World Health Organization (WHO) classification and compare with previous reports. Between 2015 and 2016, 7737 new patients with malignant lymphoma were enrolled from 31 institutes, with their clinicopathologic information obtained, and evaluated for the relative frequency of lymphoma subtypes. The relative frequency of non-Hodgkin lymphoma (NHL) was 94.8%, and that of Hodgkin lymphoma (HL) was 5.2%. B cell lymphomas accounted for 83.1% of all NHLs; T/natural killer (NK) cell lymphomas, 16.4%; and immunodeficiency-associated lymphoproliferative disorders, 0.5%. The most common NHL subtypes were diffuse large B cell (41.5%), extranodal marginal zone (MALT, 19.8%), follicular (7.5%), NK/ T cell (4.2%), and peripheral T cell lymphomas, not otherwise specific (PTCL, NOS, 3.4%). Nodular sclerosis was the predominant HL subtype (48.5%), followed by mixed cellularity (28.7%), lymphocyte-rich (6.8%), lymphocyte-depleted (1.5%), lymphocyte-predominant (2.8%), and unclassified HL (11.8%). Compared with a previous report, increased B cell lymphomas (77.6-83.1%) and slightly decreased NK/T cell lymphomas and PTCL were observed. The incidence of follicular lymphoma increased by more than 2.5-fold (2.9-7.5%). Incidence rates of newly diagnosed lymphomas were lower for HL and higher for extranodal NHL, MALT, and nasal type NK/T cell lymphomas in Korea than those in Western countries. A slight increase in the relative frequency of B cell lymphoma and a prominent increase in follicular lymphoma may be attributed to refined diagnostic criteria and Westernized disease patterns.

show abstract

Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification

Cited by 49 publications

References 26 publications

Epidemiology and Patterns of Malignant Lymphoma in Northern Saudi Arabia

Epidemiology and Patterns of Malignant Lymphoma in Northern Saudi Arabia

Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders

Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study

Contact Info

Product

Resources

About